SCHEMBL11969463

SCHEMBL11969463

CC(C)(C)OC(=O)N1CCCCC1CCN(c1ncccn1)C1Cc2ccccc2C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.46
OPRD1 P41143 1/20 0.43
AHCY P23526 3/20 0.43
ATM Q13315 2/20 0.42
CHEK2 O96017 1/20 0.41
PRMT5 O14744 1/20 0.40
GPR119 Q8TDV5 2/20 0.39
TRPV1 Q8NER1 1/20 0.38
PDE8B O95263 1/20 0.38
METTL3 Q86U44 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KDM4E B2RXH2 1/20 0.37
POLB P06746 1/20 0.37
UCHL1 P09936 2/20 0.36
USP30 Q70CQ3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11969416 0.92 KDM1A (0.44) KDM1AOPRD1AHCYATMCHEK2
SCHEMBL17167482 0.86 KDM1A (0.45) KDM1AOPRD1AHCYATMCHEK2
SCHEMBL11990571 0.86 KDM1A (0.45) KDM1AOPRD1AHCYATMCHEK2
SCHEMBL11990569 0.85 OPRD1 (0.47) KDM1AOPRD1AHCYATMPRMT5
SCHEMBL11969924 0.78 KDM1A (0.55) KDM1AOPRD1AHCYATMCHEK2
SCHEMBL11990457 0.77 DRD3 (0.34)
SCHEMBL6611590 0.75 KDM1A (0.44) KDM1AOPRD1ATMCHEK2PRMT5
SCHEMBL11969272 0.74 OPRD1 (0.52) KDM1AOPRD1AHCYATMPRMT5
SCHEMBL6609250 0.74 CHEK2 (0.56) KDM1AOPRD1ATMCHEK2PRMT5
SCHEMBL2917685 0.74 ATM (0.48) KDM1AOPRD1ATMCHEK2PDE8B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3970723-A1 AMINOINDANE COMPOUNDS FOR USE IN TREATING UROLOGICAL PAIN Asana BioSciences, LLC (US) 2022-03-23 EP disclosed
EP-3363437-B1 AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN ENDO PHARMACEUTICALS SOLUTIONS (US) 2021-07-28 EP disclosed
EP-3363437-B1 AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN ENDO PHARMACEUTICALS SOLUTIONS (US) 2021-07-28 EP disclosed
EP-3363437-A1 AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN Endo Pharmaceuticals Solutions Inc. (US) 2018-08-22 EP disclosed
EP-2675787-B1 AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN ENDO PHARMACEUTICALS INC (US) 2018-03-28 EP disclosed
EP-2675787-B1 AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN ENDO PHARMACEUTICALS INC (US) 2018-03-28 EP disclosed
US-9375423-B2 Use of aminoindane compounds in treating overactive bladder and interstitial cystitis ASANA BIOSCIENCES, LLC (US) 2016-06-28 US disclosed
US-9375423-B2 Use of aminoindane compounds in treating overactive bladder and interstitial cystitis ASANA BIOSCIENCES, LLC (US) 2016-06-28 US disclosed
US-20150290182-A1 USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS ASANA BIOSCIENCES, LLC (US) 2015-10-15 US disclosed
US-20150290182-A1 USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS ASANA BIOSCIENCES, LLC (US) 2015-10-15 US disclosed
US-8865741-B2 Aminoindane compounds and use thereof in treating pain ASANA BIOSCIENCES, LLC (US) 2014-10-21 US disclosed
US-8865741-B2 Aminoindane compounds and use thereof in treating pain ASANA BIOSCIENCES, LLC (US) 2014-10-21 US disclosed
US-20140051702-A1 Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis ENDO PHARMACEUTICALS INC. (US) 2014-02-20 US disclosed
US-20140051702-A1 Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis ENDO PHARMACEUTICALS INC. (US) 2014-02-20 US disclosed
WO-2014028675-A1 USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS ENDO PHARMACEUTICALS INC. (US) 2014-02-20 WO disclosed
WO-2014028675-A1 USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS ENDO PHARMACEUTICALS INC. (US) 2014-02-20 WO disclosed
EP-2675787-A1 AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN Endo Pharmaceuticals Inc. (US) 2013-12-25 EP disclosed
WO-2012112969-A1 AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN ENDO PHARMACEUTICALS INC. (US) 2012-08-23 WO disclosed
US-20120214809-A1 Aminoindane Compounds and Use Thereof in Treating Pain Libertas Bio, Inc. 2012-08-23 US disclosed
US-20120214809-A1 Aminoindane Compounds and Use Thereof in Treating Pain Libertas Bio, Inc. 2012-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214809-A1 Aminoindane Compounds and Use Thereof in Treating Pain TRPA1, TRPV1, TRPV2 KDM1A 717/4885OPRD1 47/4885AHCY 3571/4885
US-20140051702-A1 Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis IDO1, IDO2, SLC1A2 KDM1A 2847/4885OPRD1 51/4885AHCY 320/4885
US-20150290182-A1 USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS IDO1, IDO2, SLC1A2 KDM1A 2847/4885OPRD1 51/4885AHCY 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.